Author:
Feller John K,Yang Shi,Mahalingam Meera
Publisher
Springer Science and Business Media LLC
Subject
Pathology and Forensic Medicine
Reference29 articles.
1. Wan P, Garnett M, Roe SM et al Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855–867.
2. Wajapeyee N, Serra R, Zhu X et al Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008;132:363–374.
3. Capper D, Preusser M, Habel A et al Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122:11–19.
4. Yuen S, Davies H, Chan T et al Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62:6451–6455.
5. Cohen Y, Xing M, Mambo E et al BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625–627.
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluation of HSP-27, BAP1, BRAF V600E, CCR7, and PD-L1 expression in uveal melanoma on enucleated eyes and metastatic liver tumors;The International Journal of Biological Markers;2022-03-28
2. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting;Pathology;2022-02
3. Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era;Diagnostics;2021-06-18
4. Ultrasound-Mediated Microbubble Destruction Inhibits Skin Melanoma Growth by Affecting YAP1 Translation Using Ribosome Imprinting Sequencing;Frontiers in Oncology;2021-04-29
5. Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2;Diagnostics;2021-03-27